In a reorganization first divulged in January, Philadelphia-based Spark Therapeutics, Roche’s gene therapy subsidiary, is letting go of 298 employees in Philadelphia. The cuts will come in three waves starting May 9 and ending Dec. 31, according to a Worker Adjustment and Retraining Notification notice.
